increased insulin sensitivity and soft tissue regression usually accompany growth hormone ch1nges of this magnitude. However, the most striking changes in soft tissue and bone are observed when the growth hormone levels fall below 5 ng/ml.
The Use of Yttrium 90 Implantation in the Treatment ofAcromegaly This paper reviews the results of implantation of radioactive gold ('95Au) and yttrium (90Y) in our first 80 patients implanted from 1958 to 1967 inclusive and followed for at least one year. The implantation procedure has been described (Joplin et al. 1961 ) and, as shown in Table 1 , the planned dose to the diaphragma sellm and gland periphery has been increased over these years. We have aimed at adequate treatment of the tumour without inducing hypopituitarism. 1Present address: Department of Medicine, Toronto General Hospital, Toronto, Canada Table 1 Pitu"rit implantation in acromegaly (195-December 1967) (Hartog et al. 1965) , the overall clinical response is designated as satisfactory, partial or nil. A satisfactory response means full relief of symptoms, visible regression of signs of acromegaly, return to normal of the insulin resistance index (Fraser et al. 1962 ) and/or improvement in glucose tolerance where this is abnormal. A partial response fulffils some but not all ofthese criteria.
Among the whole group, at one year or more following the last implant, 53 % had a satisfactory response and nearly all showed some improvement. Fig 1 shows the outcome for the various irradiation dose subgroups. At our current dose plan of 50,000 rads, about half have had a satisfactory response and all the remainder a partial response. Relief of partsthesim, due presumably to soft tissue changes, has occurred within a few weeks, while reduction in the size of hands and feet has been noticed three months after implant; some changes are still progressive in some of the patients who have been followed for as long as nine years. Headaches were abolished in 20 of 40 patients and improved in all but 2 of the remainder; paresthesix were lost in 18 of 27 patients and improved in all but 5 of the (13 ) 4 (4) remamnder. In all 5 patients with visual field defects, considerable improvement in fields and acuity was observed (details to be reported elsewhere).
Biochemical Response
The insulin resistance index was initially abnormal (i.e. greater than 142) in 79% of 42 nondiabetic patients; after treatment it was abnormal in only 29%, the mean value falling from 165 to 120.
Of the 8 patients with clinical diabetes who were followed up, glucose tolerance became normal in 4 and showed only mild chemical abnormalities in 2; in 2 insulin-requiring patients, the diabetes was unchanged. In the group of 11 patients with chemical diabetes, glucose tolerance became normal in 5.
The serum growth hormone (GH) levels in all 34 patients in whom measurements were made before, and again at least one year after, implant are shown in Fig 2 ( implantation itself has been infection in the tumour, which was usually a sequel of overt cerebrospinal fluid rhinorrhcea. Such a local infection can readily spread to give meningitis. Among the last 30 implants giving 50,000 rads (January 1968 to March 1969 there has been no instance of local infection, after the introduction of two important measures:
(1) Adequate pre-implant antiseptic treatment with chlorhexidine (Hibitane) (1/1,000) nasal spray, combined with antibiotic cover with cloxacillin for five days after implant.
(2) Starting trimethoprim (250 mg) and sulphamethoxazole (500 mg) twice daily immediately a cerebrospinal fluid leak is reported, and continuing this until the leak either heals spontaneously or is repaired. Loss of anterior pituitary function to the extent that cortisone or thyroxine became necessary occurred after 28 % of implants (Table 2 ) or in 20% if we exclude those deliberately given total ablation doses. Loss of ACTH or TSH was not necessarily combined with loss of GH secretion. Among 15 patients attaining normal GH levels, 11 also lost other anterior pituitary function; among the 18 hypopituitary patients needing thyroxine and cortisone, there were 7 who still had abnormally high-GH levels (Fig 3) .
Diabetes insipidus occurred after 16 implants (17%), but in only 4 has permanent vasopressin treatment been required. Hyponatremia due to 'inappropriate' ADH was observed after one of the implants.
Conclusions
(1) A satisfactory clinical response was achieved by yttrium implantation in more than half of 80 acromegalic patients. Hypopituitarism occurred in a quarter. Cerebrospinal fluid rhinorrhea occurred in 13 % and local infection in 12%.
(2) Considerable improvement in the visual field defects was observed in all 5 patients so affected.
(3) The changes observed in serum GH levels did not always mirror the clinical response; a satisfactory clinical response appeared to need both a pronounced percentage fall as well as a fall to below an absolute level between 10-50 ng/ml.
